Ultrasound-controlled cryoneurolysis for peripheral mononeuropathies: a retrospective cohort study.
Zdenek NemecekConstanze SturmAnna C RauenFlorian ReisigKonrad StreitbergerMichael Alexander HarnikPublished in: Pain management (2023)
Aim: Cryoneurolysis is a potential therapy for peripheral mononeuropathies, but randomized studies of its effects on the duration of pain reduction are lacking. Methods: This retrospective cohort study evaluated the analgesic effects of cryoneurolysis on patients with refractory peripheral mononeuropathy. We included 24 patients who underwent ultrasound-guided cryoneurolysis between June 2018 and July 2022. The daily maximum pain level was recorded using a numerical rating scale before and 1, 3 and 6 months after the procedure. Results: At 1 month, 54.2% of patients reported pain reduction of at least 30%. This percentage was significantly lower at 3 and 6 months (13.8 and 9.1%, respectively). Conclusion: Our results suggest that repeated cryoneurolysis may be a viable treatment for refractory mononeuropathy. Further investigations are needed.
Keyphrases
- end stage renal disease
- chronic pain
- ejection fraction
- neuropathic pain
- newly diagnosed
- chronic kidney disease
- ultrasound guided
- pain management
- magnetic resonance imaging
- open label
- clinical trial
- randomized controlled trial
- minimally invasive
- risk assessment
- climate change
- spinal cord
- combination therapy
- human health
- replacement therapy
- phase ii
- chemotherapy induced